TAKEDA PHARMACEUTICAL CO LTD
TKPHFDrugs in Pipeline
88
Phase 3 Programs
70
Upcoming Catalysts
8
Next Catalyst
Jun 11, 2026
7wMarket Overview
Stock performance and key metrics
8 upcoming, 0 past
Azilsartan medoxomil with or without add-on chlorthalidone
Hypertension
Vedolizumab SC
Colitis, Ulcerative
Lapaquistat acetate
Hypercholesterolemia
TAK-788
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAP-144-SR(6M)
Premenopausal Breast Cancer
Glimepiride
Diabetic Patients
Teduglutide
Short Bowel Syndrome
Epoetin Alfa
Myelodysplastic Syndrome
Mezagitamab
Kidney Disease
Tetravalent Dengue Vaccine (TDV)
Dengue Fever
Pioglitazone and metformin
Diabetes Mellitus
TAK-881
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
omega-3-acid ethyl esters 90 (TAK-085)
Hypertriglyceridemia
TAK-625
Progressive Familial Intrahepatic Cholestasis (PFIC)
TAK-861
Narcolepsy Type 1
Lanadelumab
Hereditary Angioedema (HAE)
TAK-019
Coronavirus Disease (COVID-19)
Valsartan
Hypertension
Elritercept
Myelodysplastic Syndromes
Ponatinib
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Glimepiride and Metformin
Diabetes Mellitus
Relugolix
Uterine Fibroids
Apremilast
Plaque Psoriasis
Bismuth-Containing Quadruple Therapy
Gastric Ulcer
Vedolizumab IV
Ulcerative Colitis
Vortioxetine
Depressive Disorder, Major
TAK-438
Duodenal Ulcer
Lansoprazole
Gastric Ulcers
Alogliptin
Type 2 Diabetes Mellitus
Pioglitazone
Diabetes Mellitus
Vedolizumab
Ulcerative Colitis
Zasocitinib
Plaque Psoriasis
Febuxostat
Hyperuricosuria
Pantoprazole
Gastroesophageal Reflux Disease (GERD)
Ramelteon
Chronic Insomnia
Metformin
Diabetes Mellitus
TDV
Healthy Volunteers
Lubiprostone
Chronic Idiopathic Constipation
Febuxostat IR
Gout
Lapaquistat acetate and atorvastatin
Dyslipidemia
Vonoprazan
Helicobacter Pylori
Alogliptin and insulin
Diabetes Mellitus
Alogliptin and metformin
Diabetes Mellitus
Trelagliptin 25 mg
Type 2 Diabetes Mellitus
Alogliptin and glimepiride
Type 2 Diabetes Mellitus
Allopurinol
Gout
Alogliptin 25 mg
Diabetes Mellitus
Duloxetine
Depressive Disorder, Major
IGI, 10%
Multiple Myeloma
Soticlestat
15q Duplication Syndrome
Alogliptin and voglibose
Type 2 Diabetes Mellitus
SYR-472
Type 2 Diabetes Mellitus
Dexlansoprazole MR
Esophagitis, Reflux
Dexlansoprazole
Gastroesophageal Reflux Disease (GERD)
TAK-771
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Fazirsiran Injection
Alpha1-Antitrypsin Deficiency
Ixazomib
Multiple Myeloma
Maribavir
Cytomegalovirus (CMV)
Azilsartan medoxomil
Hypertension
TAK-279
Ulcerative Colitis
Azilsartan medoxomil and chlorthalidone
Safety
Dexamethasone
Relapsed Multiple Myeloma
Chlorthalidone
Hypertension
Actovegin
Post-Stroke Cognitive Impairment (PSCI)
Darvadstrocel
Complex Perianal Fistulas in Adult Participants With Crohn's Disease
Azilsartan
Pediatric Hypertension
Lenalidomide
Relapsed Multiple Myeloma
TAK-875
Diabetes Mellitus
Alogliptin and pioglitazone
Type 2 Diabetes Mellitus
TVP-1012 1mg
Parkinson's Disease
TAK-935
Epilepsy
Cabozantinib
Advanced Hepatocellular Carcinoma
Voglibose
Diabetes Mellitus, Type 2
TAK-583
Diabetic Neuropathies
TAK-755
Thrombotic Thrombocytopenic Purpura (TTP)
TAK-385
Endometriosis
TAK-360
Narcolepsy Type 2
TAK-954
Diabetic Gastroparesis
Sitagliptin
Diabetes Mellitus, Type 2
Namilumab
Plaque Psoriasis
Peginesatide
Anemia
NoV GI.1/GII.4 Bivalent VLP Vaccine
Healthy Volunteers
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Colorectal Carcinoma
Brentuximab Vedotin
Hodgkin Disease
TAK-850
Influenza
Niraparib
Ovarian Cancer
TAK-079
Myasthenia Gravis
Idursulfase-IT
Hunter Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Azilsartan medoxomil with or without add-on chlorthalidone | Phase 3 | Hypertension | - | - |
Vedolizumab SC | Phase 3 | Colitis, Ulcerative | - | - |
Lapaquistat acetate | Phase 3 | Hypercholesterolemia | - | - |
TAK-788 | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | - | - |
TAP-144-SR(6M) | Phase 3 | Premenopausal Breast Cancer | - | - |
Glimepiride | Phase 3 | Diabetic Patients | - | - |
Teduglutide | Phase 3 | Short Bowel Syndrome | - | - |
Epoetin Alfa | Phase 3 | Myelodysplastic Syndrome | - | - |
Mezagitamab | Phase 3 | Kidney Disease | - | - |
Tetravalent Dengue Vaccine (TDV) | Phase 3 | Dengue Fever | - | - |
Pioglitazone and metformin | Phase 3 | Diabetes Mellitus | - | - |
TAK-881 | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
omega-3-acid ethyl esters 90 (TAK-085) | Phase 3 | Hypertriglyceridemia | - | - |
TAK-625 | Phase 3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | - | - |
TAK-861 | Phase 3 | Narcolepsy Type 1 | - | - |
Lanadelumab | Phase 3 | Hereditary Angioedema (HAE) | - | - |
TAK-019 | Phase 3 | Coronavirus Disease (COVID-19) | - | - |
Valsartan | Phase 3 | Hypertension | - | - |
Elritercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Ponatinib | Phase 3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | - | - |
Glimepiride and Metformin | Phase 3 | Diabetes Mellitus | - | - |
Relugolix | Phase 3 | Uterine Fibroids | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
Bismuth-Containing Quadruple Therapy | Phase 3 | Gastric Ulcer | - | - |
Vedolizumab IV | Phase 3 | Ulcerative Colitis | - | - |
Vortioxetine | Phase 3 | Depressive Disorder, Major | - | - |
TAK-438 | Phase 3 | Duodenal Ulcer | - | - |
Lansoprazole | Phase 3 | Gastric Ulcers | - | - |
Alogliptin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Pioglitazone | Phase 3 | Diabetes Mellitus | - | - |
Vedolizumab | Phase 3 | Ulcerative Colitis | - | - |
Zasocitinib | Phase 3 | Plaque Psoriasis | - | - |
Febuxostat | Phase 3 | Hyperuricosuria | - | - |
Pantoprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
Ramelteon | Phase 3 | Chronic Insomnia | - | - |
Metformin | Phase 3 | Diabetes Mellitus | - | - |
TDV | Phase 3 | Healthy Volunteers | - | - |
Lubiprostone | Phase 3 | Chronic Idiopathic Constipation | - | - |
Febuxostat IR | Phase 3 | Gout | - | - |
Lapaquistat acetate and atorvastatin | Phase 3 | Dyslipidemia | - | - |
Vonoprazan | Phase 3 | Helicobacter Pylori | - | - |
Alogliptin and insulin | Phase 3 | Diabetes Mellitus | - | - |
Alogliptin and metformin | Phase 3 | Diabetes Mellitus | - | - |
Trelagliptin 25 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Alogliptin and glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Allopurinol | Phase 3 | Gout | - | - |
Alogliptin 25 mg | Phase 3 | Diabetes Mellitus | - | - |
Duloxetine | Phase 3 | Depressive Disorder, Major | - | - |
IGI, 10% | Phase 3 | Multiple Myeloma | - | - |
Soticlestat | Phase 3 | 15q Duplication Syndrome | - | - |
Alogliptin and voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
SYR-472 | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Dexlansoprazole MR | Phase 3 | Esophagitis, Reflux | - | - |
Dexlansoprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
TAK-771 | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
Fazirsiran Injection | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
Ixazomib | Phase 3 | Multiple Myeloma | - | - |
Maribavir | Phase 3 | Cytomegalovirus (CMV) | - | - |
Azilsartan medoxomil | Phase 3 | Hypertension | - | - |
TAK-279 | Phase 3 | Ulcerative Colitis | - | - |
Azilsartan medoxomil and chlorthalidone | Phase 3 | Safety | - | - |
Dexamethasone | Phase 3 | Relapsed Multiple Myeloma | - | - |
Chlorthalidone | Phase 3 | Hypertension | - | - |
Actovegin | Phase 3 | Post-Stroke Cognitive Impairment (PSCI) | - | - |
Darvadstrocel | Phase 3 | Complex Perianal Fistulas in Adult Participants With Crohn's Disease | - | - |
Azilsartan | Phase 3 | Pediatric Hypertension | - | - |
Lenalidomide | Phase 3 | Relapsed Multiple Myeloma | - | - |
TAK-875 | Phase 3 | Diabetes Mellitus | - | - |
Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
TVP-1012 1mg | Phase 3 | Parkinson's Disease | - | - |
TAK-935 | Phase 2 | Epilepsy | - | - |
Cabozantinib | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
Voglibose | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
TAK-583 | Phase 2 | Diabetic Neuropathies | - | - |
TAK-755 | Phase 2 | Thrombotic Thrombocytopenic Purpura (TTP) | - | - |
TAK-385 | Phase 2 | Endometriosis | - | - |
TAK-360 | Phase 2 | Narcolepsy Type 2 | - | - |
TAK-954 | Phase 2 | Diabetic Gastroparesis | - | - |
Sitagliptin | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Namilumab | Phase 2 | Plaque Psoriasis | - | - |
Peginesatide | Phase 2 | Anemia | - | - |
NoV GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Healthy Volunteers | - | - |
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Phase 2 | Colorectal Carcinoma | - | - |
Brentuximab Vedotin | Phase 2 | Hodgkin Disease | - | - |
TAK-850 | Phase 2 | Influenza | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
TAK-079 | Phase 2 | Myasthenia Gravis | - | - |
Idursulfase-IT | Phase 2 | Hunter Syndrome | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)